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Letter to the Editor
Bordetella holmesii endocarditis in a patient
with systemic lupus erythematous treated
with immunosuppressive agents
Sir,
Bordetella holmesii, formerly designated as CDC
non-oxidizer group 2, was recently classified as a
member of the genus Bordetella.1
This pathogen has been reported as a rare cause of
bactaeremia, respiratory tract infection, and endocar-
ditis, particularly in younger patients.1,2–9 Anatomic
or functional asplenia, renal transplantation, HIV
infection, long-term steroid therapy, Hodgkin’s lym-
phoma, and chronic obstructive pulmonary disease are
all predisposing conditions for invasive disease.2–9
Bordetella spp. represents one of the non-HACEK
(Haemophilus species, Actinobacillus actinomycetem-
comitans, Cardiobacterium hominis, Eikenella corro-
dens, and Kingella species) Gram-negative rods that
can cause endocarditis.6,9 Infective endocarditis (IE)
caused by non-HACEKGram-negative bacilli is a rare
and poorly understood disease; only few cases have
been described so far and all present a high mortality
rate (24%).10
From 1972 to 2011, only two cases of Bordetella
holmesii endocarditis have been found in a review of
the English literature. The diagnosis of B. holmesii IE
was confirmed by the presence of a valvular vegetation
in only one of these two cases, and was documented
through the use of the echocardiography; in the other
case, the diagnosis was only clinically suspected.
Here we report a case of IE caused by Bordetella
holmesii in a patient affected by systemic lupus
erythematous (SLE) and receiving an immunosup-
pressive treatment with azathioprine and prednisone.
On March 2011, a 48-year-old male patient was
admitted to the Infectious Diseases Department of the
San Martino University Hospital of Genoa, Italy, due
to a long history of fever and fatigue. His medical
history included an autoimmune thyroiditis and a
recent diagnosis of SLE, which had been based on
physical examination and laboratory test results
(positivity of antinuclear antibody test).
Before this hospitalization, no organ involvement of
SLE had been described and no new sign was
diagnosed on this matter at the Infectious Diseases
Department. In his medical history, the patient had
received remittent courses of prednisone therapy
(25 mg/die) for his rheumatic conditions. On 1
February 2011, due to a persistent febrile state,
azathioprine was introduced to his therapeutic
scheme. During this period, a positron emission
tomography/computed tomography scan was per-
formed and it documented no evidence of metaboli-
cally active disease. However, due to the presence of a
diastolic murmur on auscultation, a transthoracic
echocardiography (TTE) was performed, which docu-
mented the presence of mobile vegetation on a
bicuspid aortic valve, with moderate–severe aortic
regurgitation and left ventricle overload. No lesions
compatible with Libman–Sacks endocarditis existed
prior to this episode.
The immunosuppressive therapy was then discon-
tinued and the patient was hospitalized at the
Infectious Diseases Department with the diagnosis of
suspected IE. His temperature was 36.3uC, heart rate
was 90 bpm, and blood pressure was 125/65 mmHg.
Physical examination revealed normal S1 and S2
sounds, but a 2/6 diastolic murmur on the aortic
auscultation site was detected. Laboratory test results
showed elevated C-reactive protein (90.9 mg/l, normal
range: 0–5 mg/l) and no leukocytosis. Serial sets of
blood cultures were performed and colonies of Gram-
negative rods grew from five of them. The isolated
pathogen grew on blood and chocolate agar plates
after 2 days of incubation, but showed a very limited
growth on MacConkey agar. The strain produced a
diffusible brown pigment on blood agar plate and was
catalase negative. Initially, it was not possible to
identify the isolate neither through routine laboratory
procedure by using VITEK 2 AES (BioMe´rieux,
Durham, NC, USA) nor by the API NE and NH
strips (BioMe´rieux). The strain was subsequently
identified as Bordetella holmesii by sequence analysis
of the hypervariable regions V3 and V6 of the 16S
rRNA gene; by insertion elements (IS1001, IS1002,
and IS481) analysis; by using previously describ-
ed primers and conditions, and by differential
biochemical tests (oxidase, nitrate reduction, and
urease production) used to differentiate Bordetella
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species.11–13 Antimicrobial susceptibility testing was
performed by the disk diffusion method. Results were
interpreted according both to the Clinical and
Laboratory Standard Institute break-points for fasti-
dious bacteria and break-points for members of the
family of Enterobacteriaceae [amikacin susceptible (S),
gentamicin (S), piperacillin (S), piperacillin/tazobac-
tam (S), ceftazidime (S), cefepime (S), cefotaxime
resistant (R) and aztreonam (R), imipenem (S)].14,15
Once having diagnosed the IE, an empirical anti-
microbial treatment with piperacillin/tazobactam
(4.5 g IV q6h) and gentamicin (80 mg IV q8h) was
started. On day 3, piperacillin/tazobactam was sub-
stituted by meropenem (1 g IV q8h) because anti-
microbial susceptibility patterns indicated that the
isolate (not yet identified) was probably an extended-
spectrum beta-lactamases (ESBL)-producer strain,
since all blood isolates were resistant to cefotaxime.
After 7 days of antimicrobial treatment, because of the
persistence of severe aortic regurgitation and the onset
of left ventricle overload, the patient urgently under-
went an aortic valve replacement with a mechanical
valve (St Jude 23). After surgery and antibiotic
therapy, C-reactive protein levels returned to normal
and, after 4 weeks of treatment, antimicrobial therapy
was discontinued. After the surgical procedure, a TTE
was performed, and it showed no signs of paravalvular
leaks, prosthesis dehiscence, or thrombosis. After
6 months of follow-up, the patient remained in good
clinical conditions and without bacterial recurrences.
To our knowledge, this is the first reported case of
Bordetella holmesii infection in a patient with SLE.
Bordetella spp. are traditionally regarded as human
respiratory tract colonizers. However, they have been
described as causative agents of infections such as
bactaeremia, pneumonia and, rarely, endocarditis.
Overall, only two cases of endocarditis have been
previously reported. The first patient, a 25-year-old
man who presented a medical history of radiation
therapy for stage IIA Hodgkin’s lymphoma, had a
bicuspid aortic valve and a TTE revealed the presence
of a valve vegetation. The second patient, a previously
healthy 14-year-old girl, had a thickened mitral valve
discovered at TTE.3,7
In the case presented, Bordetella holmesii IE
developed in a 48-year-old patient with SLE, pre-
viously treated with azathioprine and prednisone, who
recovered completely after surgery and 4 weeks of
antibiotic treatment. On hospital admission, we
decided to administer piperacillin-tazobactam because
of the absence of fever, the absence of severe clinical
conditions, and no reported prior antibiotic use.
However, despite the absence of a clinical worsening,
we considered the choice of a new highly bactericidal
drug with a potent and rapid activity, because of the
potential severity of the infection. We wanted to be
cautious, thinking about the increasing incidence of
infections caused by ESBLs producing bacteria and
considering that the activity of piperacillin-tazobac-
tam on ESBLs producers cannot be easily predicted in
vitro.16 Therefore, we decided to substitute piperacil-
lin/tazobactam with meropenem, even though the
isolate was susceptible to piperacillin/tazobactam in
vitro. As predicted, blood cultures performed after
3 days of piperacillin/tazobactam therapy were posi-
tive for Gram-negatives rods, while blood cultures
performed after the introduction of meropenem were
negative, supporting our choice. Moreover, the
isolated rod, subsequently identified as Bordetella
holmesii, was in vitro resistant to cefotaxime, suggest-
ing the production of ESBLs.
In a previously published analysis of 26 strains of B.
holmesii, MIC ranges of penicillins and third-genera-
tion cephalosporins were elevated (varying from 8 to
.16 mg/l for penicillin, from 1 to 8 mg/l for ampi-
cillin, and from 4 to .8 mg/l for cefotaxime),
suggesting the possibility of a poor clinical response
to these drugs.8 More data are needed to achieve an
adequate interpretation of in vitro Bordetella holmesii
susceptibility. Although B. holmesii has been isolated
from cultures of US patients nasopharyngeal speci-
mens, the source of Bordetella bactaeremia remains
uncertain.17 Modes of acquisition also remain to be
identified, as no person-to-person transmission has
been described.9 Bordetella holmesii may act as an
opportunistic pathogen in particular clinical condi-
tions such as hyposplenism or asplenia, conditions
that are also associated with SLE and infections with
encapsulated pathogens.18 While the presence of a
polysaccharide capsule in Bordetella holmesii strains
remains unknown, other Bordetella spp. are likely to
encode a capsule.19 Therefore, even if the paucity of
available data does not allow a clear identification of
predisposing factors for invasive infections by B.
holmesii, we want to emphasize that, despite the small
number of reports, underlining immunocompromising
conditions, such as steroid treatment or haematologi-
cal malignancies, hyposplenism, and the presence
of a native bicuspid aortic valve may be all factors
associated with the risk of Bordetella holmesii
disease.
Matteo Bassetti, Elena Nicco,
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